LSUHSC Minority Based Community Clinical Oncology

路易斯安那州立大学健康科学中心少数族裔社区临床肿瘤学项目（LSUHSC MBCCOP）仍然是东南部少数群体获得和参与临床试验的绝佳工具 方面应受中华路易斯安那州的几种常见恶性肿瘤的发病率在统计学上显著增加， 美国其他地区（监测、流行病学和最终结果[SEER]估计）。重要的是， 大约70%的患者在国家医疗系统最大的城市医院（医疗中心）就诊， 路易斯安那州在新奥尔良[MCLNO]）是非洲裔美国人。不幸的是，非裔美国人传统上 在获得和参与肿瘤学临床试验方面代表性不足。这种试验用于提供切割 边缘疗法和预防策略。此外，少数民族对临床 试验还可以提供关于潜在药物基因组学差异的临床结局的重要信息， 非裔美国人对白人。然而，LSUHSC MBCCOP寻求减少试验参与方面的差距 非裔美国人和白种人之间的差异重要的是，MBCCOP为社区提供的临床试验 包括治疗和预防目标。LSUHSC MBCCOP的目标包括：1）增加 通过针对多层次患者的干预措施，少数群体获得和参与治疗性临床试验 在乎2)通过干预措施，增加少数群体获得和参与癌症预防临床试验的机会， 多层次的病人护理。3)为了评估患者进入和参与临床试验的障碍， 城市学术医院系统总之，LSUHSC MBCCOP旨在增加 少数民族人口通过教育和投资发起了对这些障碍的评估。

The Louisiana State University Health Sciences Center Minority Based Community Clinical Oncology Program (LSUHSC MBCCOP) remains an excellent vehicle for clinical trials access and participation in the minority population of Southeast Louisiana. Louisiana has a statistically significantly increased incidence of several common malignancies over the remainder of the United States (Surveillance, Epidemiology and End Results [SEER] estimate). Importantly, approximately 70% of patients seen in the largest urban hospital of the state medical system (The Medical Center of Louisiana at New Orleans [MCLNO]) are African American. Unfortunately, African Americans have traditionally remained underrepresented in terms of access to and participation in oncology clinical trials. Such trials serve to provide cutting edge therapies and prevention strategies to the local community. Additionally, subset evaluations of minorities on clinical trials may also provide important information on the clinical outcomes of potential pharmacogenomic differences in African Americans versus Caucasians. However, the LSUHSC MBCCOP seeks to decrease the gap in trials participation between African Americans and Caucasians. Importantly, the clinical trials that the MBCCOP provides for the community encompass both therapeutic and prevention objectives. The aims of the LSUHSC MBCCOP include 1) To increase minority access to and participation in therapeutic clinical trials through interventions targeting multiple levels of patient care. 2) To increase minority access to and participation in cancer prevention clinical trials through interventions targeting multiple levels of patient care. 3) To evaluate barriers to access and participation in clinical trials by patients in a large, urban, academic hospital system. In summary, the LSUHSC MBCCOP seeks to increase trials participation of the minority population through education and investi_lator initiated evaluation of barriers to these _loals.